4.7 Article

MS quality of life, depression, and fatigue improve after mindfulness training A randomized trial

Journal

NEUROLOGY
Volume 75, Issue 13, Pages 1141-1149

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f4d80d

Keywords

-

Funding

  1. Swiss National Science Foundation [3200B0-112604]
  2. Stanley T. Johnson Foundation
  3. Swiss Multiple Sclerosis Foundation
  4. Sanofi-Aventis
  5. Merck Serono
  6. Biogen-Dompe AG
  7. Swiss Cancer League
  8. Swiss MS Society
  9. Gianni Rubatto Foundation (Zurich)
  10. Acorda Therapeutics Inc.
  11. Actelion Pharmaceuticals Ltd.
  12. Abbott
  13. AstraZeneca
  14. Bayhill Therapeutics
  15. Bayer Schering Pharma
  16. Biogen Idec
  17. Boehringer Ingelheim
  18. Centocor Ortho Biotech Inc.
  19. Eisai Inc.
  20. Genzyme Corporation
  21. GlaxoSmithKline
  22. Immune Response Corporation
  23. MediciNova, Inc.
  24. Neurocrine Biosciences
  25. Novartis
  26. Roche
  27. Teva Pharmaceutical Industries Ltd.
  28. UCB
  29. Wyeth
  30. NIH [R01-MH059708, R01-HD043323, R34 MH078922]
  31. US Veterans Administration HSRD

Ask authors/readers for more resources

Objective: Health-related quality of life (HRQOL) is often much reduced among individuals with multiple sclerosis (MS), and incidences of depression, fatigue, and anxiety are high. We examined effects of a mindfulness-based intervention (MBI) compared to usual care (UC) upon HRQOL, depression, and fatigue among adults with relapsing-remitting or secondary progressive MS. Methods: A total of 150 patients were randomly assigned to the intervention (n = 76) or to UC (n = 74). MBI consisted of a structured 8-week program of mindfulness training. Assessments were made at baseline, postintervention, and 6 months follow-up. Primary outcomes included disease-specific and disease-aspecific HRQOL, depression, and fatigue. Anxiety, personal goal attainment, and adherence to homework were secondary outcomes. Results: Attrition was low in the intervention group (5%) and attendance rate high (92%). Employing intention-to-treat analysis, MBI, compared with UC, improved nonphysical dimensions of primary outcomes at postintervention and follow-up (p < 0.002); effect sizes, 0.4-0.9 posttreatment and 0.3-0.5 at follow-up. When analyses were repeated among subgroups with clinically relevant levels of preintervention depression, fatigue, or anxiety, postintervention and follow-up effects remained significant and effect sizes were larger than for the total sample. Conclusions: In addition to evidence of improved HRQOL and well-being, these findings demonstrate broad feasibility and acceptance of, as well as satisfaction and adherence with, a program of mindfulness training for patients with MS. The results may also have treatment implications for other chronic disorders that diminish HRQOL. Classification of evidence: This trial provides Class III evidence that MBI compared with UC improved HRQOL, fatigue, and depression up to 6 months postintervention. Neurology (R) 2010;75:1141-1149

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available